PR96146

Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

BEIJING dldate May 24, 2022 /PRNewswire=KYODO JBN/ --

Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals

(Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two

posters at the 2022 ASCO Annual Meeting, taking place in Chicago, IL and

virtually from June 3-7, 2022. The posters describe updates from two phase I

clinical studies in Australia for internally developed monoclonal antibodies

(mAbs) YH003 (anti-CD40, abstract # 2603) and YH001 (anti-CTLA-4, abstract #

2602). Both YH003 and YH001 demonstrate favorable safety and tolerability

profiles and preliminary efficacy when administered in combination with

anti-PD-1 mAb to patients with advanced solid tumors.

The details of the presentations are as follows:

Title         

A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal

antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with

advanced solid tumors.

(https://meetings.asco.org/abstracts-presentations/210362)

Corresponding author

Dr. Jermaine Coward

Trial

NCT04481009

Abstract number

2603

Session

Poster Session 3: Developmental Therapeutics—Immunotherapy

Title

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal

antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients

with advanced solid tumors.

(https://meetings.asco.org/abstracts-presentations/210326)

Corresponding author

Dr. Vinod Ganju

Trial

NCT04357756

Abstract number

2602

Session

Poster Session 3: Developmental Therapeutics—Immunotherapy

Both posters will be presented in-person on Sunday, June 5 from 8:00 AM–11:00

AM CT.

About YH003

YH003 is a humanized IgG2 agonistic CD40 antibody. Whether used as a single

agent or in combination with anti-PD-1 mAb drugs, YH003 demonstrated strong

anti-tumor effects against multiple tumor models in Biocytogen's humanized CD40

mice, without exhibiting hepatotoxicity or other toxicities. Pharmacodynamic

studies in mice indicate that YH003 significantly increased the infiltration of

anti-tumor T cells into tumors. Currently, YH003 is undergoing phase II

multi-regional clinical trials (MRCTs) for the treatment of patients with

unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC).

About YH001

YH001 is an anti-CTLA-4 monoclonal antibody. CTLA-4 is a key target for tumor

immunotherapies, due to the potential to enhance the immune response to tumor

cells and promote removal of regulatory T cells from the tumor

microenvironment. Blocking the inhibitory signals from both CTLA-4 and PD-1 to

enhance the anti-tumor responses is considered a promising tumor immunotherapy,

as they control different types of T cells. Currently, YH001 is undergoing

phase II MRCTs for the treatment of patients with advanced non-small cell lung

cancer (NSCLC) and hepatocellular carcinoma (HCC). Moreover, Biocytogen/Eucure

Biopharma has entered into a collaborative partnership agreement with TRACON

Pharmaceuticals (NASDAQ: TCON) for the development of YH001 for multiple

oncology indications, including soft tissue sarcoma, in North America.

About Eucure Biopharma

As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the

mission of clinical development for Biocytogen's R&D pipelines. Relying on a

strong clinical development team and extensive clinical development experience,

Eucure Biopharma focuses on antibody drug therapy for oncology and other

indications. The company has established a product pipeline for more than 10

targets, with two products in phase II MRCT and two in phase I. For more

information, please visit www.eucure.com (http://www.eucure.com/).

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology

company that drives the research and development of novel antibody-based drugs

with innovative technologies. Using its proprietary RenMabTM /RenLite® mouse

platforms for fully human monoclonal and bispecific antibody development,

Biocytogen has integrated its in vivo drug efficacy screening platforms and

strong clinical development expertise to streamline the entire drug development

process. Biocytogen is undertaking a large-scale project to develop antibody

drugs for more than 1000 targets, known as Project Integrum, and has entered

ongoing collaborations with dozens of partners worldwide to produce a variety

of first-in-class and/or best-in-class antibody drugs. The company's pipeline

includes 12 core products, among which two products are in phase II MRCTs and

two products are in phase I. Headquartered in Beijing, Biocytogen has branches

in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more

information, please visit www.biocytogen.com (http://www.biocytogen.com/).

SOURCE:  Biocytogen

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=421880